Payment overview · 2025
General Payments
$492.32
24 reported records · 12 companies
Healthcare provider profile · identity verified
John A Abrams, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · AUBURN, AL · NPI 1891835294
Verified facts
What the public records show
CMS Open Payments records show John A Abrams, M.D. received $492.32 in general payments during 2025 across 24 reported records.
AstraZeneca Pharmaceuticals LP accounted for 30.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $151.96 | 30.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.06 | 10.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.75 | 10.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.71 | 7.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $35.69 | 7.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $34.00 | 6.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.31 | 6.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.27 | 5.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.00 | 4.7% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $17.62 | 3.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.31 | 3.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.64 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $492.32 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $89.03 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $45.06 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $36.71 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $35.69 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $34.00 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $31.69 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.69 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31.31 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.18 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $28.27 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 115 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 116 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 159 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
64 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
115 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
116 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
159 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
156 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
28 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 529 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 413 | 115 |
| Gabapentin | Gabapentin | 344 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 320 | 76 |
| Losartan Potassium | Losartan Potassium | 313 | 99 |
| Pantoprazole Sodium | Pantoprazole Sodium | 300 | 86 |
| Atorvastatin Calcium | Atorvastatin Calcium | 257 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 199 | 82 |
| Tramadol Hcl | Tramadol Hcl | 187 | 67 |
| Alprazolam | Alprazolam | 173 | 61 |
| Meloxicam | Meloxicam | 166 | 48 |
| Omeprazole | Omeprazole | 163 | 59 |
| Ozempic | Semaglutide | 159 | 32 |
| Potassium Chloride | Potassium Chloride | 157 | 57 |
| Eliquis | Apixaban | 156 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 154 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 150 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 137 | 56 |
| Quetiapine Fumarate | Quetiapine Fumarate | 135 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 131 | 25 |
| Trazodone Hcl | Trazodone Hcl | 131 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 116 | 52 |
| Mounjaro | Tirzepatide | 116 | 16 |
| Farxiga | Dapagliflozin Propanediol | 115 | 26 |
| Oxycodone Hcl | Oxycodone Hcl | 114 | 26 |
| Sertraline Hcl | Sertraline Hcl | 114 | 43 |
| Metformin Hcl Er | Metformin Hcl | 104 | 44 |
| Simvastatin | Simvastatin | 104 | 34 |
| Furosemide | Furosemide | 103 | 44 |
| Temazepam | Temazepam | 99 | 17 |
| Carvedilol | Carvedilol | 96 | 32 |
| Lisinopril | Lisinopril | 95 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 37 |
| Bupropion Xl | Bupropion Hcl | 88 | 26 |
| Clonazepam | Clonazepam | 86 | 19 |
| Celecoxib | Celecoxib | 85 | 30 |
| Prednisone | Prednisone | 83 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 73 | 26 |
| Allopurinol | Allopurinol | 69 | 21 |
| Lorazepam | Lorazepam | 68 | 27 |
| Metformin Hcl | Metformin Hcl | 67 | 23 |
| Synthroid | Levothyroxine Sodium | 64 | 19 |
| Fluconazole | Fluconazole | 63 | 24 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 62 | 47 |
| Famotidine | Famotidine | 60 | 21 |
| Mirtazapine | Mirtazapine | 60 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 27 |
| Fentanyl | Fentanyl | 59 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 58 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 53 | 13 |
| Valsartan | Valsartan | 53 | 19 |
| Ezetimibe | Ezetimibe | 52 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 12 |
| Azelastine Hcl | Azelastine Hcl | 50 | 20 |
| Methylprednisolone | Methylprednisolone | 49 | 44 |
| Azithromycin | Azithromycin | 48 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 16 |
| Memantine Hcl | Memantine Hcl | 45 | 15 |
| Montelukast Sodium | Montelukast Sodium | 44 | 17 |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 40 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 35 |
| Torsemide | Torsemide | 40 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | 13 |
| Naproxen | Naproxen | 38 | 13 |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 24 |
| Morphine Sulfate Er | Morphine Sulfate | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 12 |
| Pregabalin | Pregabalin | 34 | 13 |
| Valacyclovir | Valacyclovir Hcl | 34 | 15 |
| Clobetasol Propionate | Clobetasol Propionate | 33 | 22 |
| Diazepam | Diazepam | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | 12 |
| Levofloxacin | Levofloxacin | 33 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 33 | suppressed |
| Atenolol | Atenolol | 32 | 13 |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Loperamide | Loperamide Hcl | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Sotalol | Sotalol Hcl | 29 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 28 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 28 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 27 |
| Cephalexin | Cephalexin | 27 | 25 |
| Ondansetron Odt | Ondansetron | 27 | 21 |
| Jardiance | Empagliflozin | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | 11 |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Methylphenidate Hcl Er (Cd) | Methylphenidate Hcl | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 18 |
| Glimepiride | Glimepiride | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Nadolol | Nadolol | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Xtampza Er | Oxycodone Myristate | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Methylphenidate Hcl Cd | Methylphenidate Hcl | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | 11 |
| Telmisartan | Telmisartan | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $492.32 · 24 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Cologuard Collection Kit, FARXIGA, KISUNLA, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, Quviviq, REPATHA, REXULTI, Rybelsus, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error